Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma.

MLA

Lu, Xiaoxiao, et al. “Real-World Time to Discontinuation of First-Line Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” Current Medical Research and Opinion, vol. 39, no. 9, Sept. 2023, pp. 1227–35. EBSCOhost, https://doi.org/10.1080/03007995.2023.2243815.

APA

Lu, X., Emond, B., Qureshi, Z. P., Wu, L. H., Forbes, S. P., Hilts, A., Liu, S., Lafeuille, M.-H., Lefebvre, P., Huang, Q., & Rogers, K. A. (2023). Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma. Current Medical Research and Opinion, 39(9), 1227–1235. https://doi.org/10.1080/03007995.2023.2243815

Chicago

Lu, Xiaoxiao, Bruno Emond, Zaina P Qureshi, Linda H Wu, Shaun P Forbes, Annalise Hilts, Stephanie Liu, et al. 2023. “Real-World Time to Discontinuation of First-Line Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” Current Medical Research and Opinion 39 (9): 1227–35. doi:10.1080/03007995.2023.2243815.